Intralesional Therapies For Cutaneous Viral Warts A Comparative Analysis Of Vitamin D3 And Acyclovir

What this Trial Is About

This clinical trial studies whether injecting acyclovir or vitamin D3 directly into skin warts helps clear them in people aged 12 and older who have common, plantar, flat, or periungual warts. It aims to find out if either treatment leads to complete wart clearance by week 8, which treatment works better, and what side effects occur. The trial is a Phase 4 study comparing two treatment groups with 20 participants each. Participants receive injections of either acyclovir or vitamin D3 into the wart every two weeks for up to four sessions. The dose varies by wart size, with injections given at the start and repeated biweekly. Both treatments are delivered directly into the wart lesion. This comparison helps researchers evaluate the effectiveness and safety of these two intralesional therapies. During the study, participants will have photographs taken of their warts before treatment and at every visit. Clinic visits include measuring the size and number of warts. After treatment, participants are followed for up to three months to monitor wart recurrence and any side effects. The main outcome measured is wart clearance at week 8, with additional tracking of early recurrence, adverse effects, and number of treatment sessions needed.

Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir